Lithium

Lithium

SCHEMBL7181087

CCCCOc1ccc(PC(=O)c2c(C)cc(C)cc2C)c(OCCCC)c1.[Li]

nearest known ligand 0.45

Full drug profile on Sugi Atlas →

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ITGB1 P05556 1/20 0.45
ITGA4 P13612 1/20 0.45
THRA P10827 3/20 0.37
THRB P10828 3/20 0.37
KDM4E B2RXH2 1/20 0.36
CYP1A2 P05177 1/20 0.36
CYP2D6 P10635 1/20 0.36
PDE4A P27815 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
HIF1A Q16665 1/20 0.36
HDAC10 Q969S8 1/20 0.36
HDAC6 Q9UBN7 1/20 0.36
ELANE P08246 1/20 0.36
PPARG P37231 2/20 0.36
PPARA Q07869 2/20 0.36
PTGES O14684 1/20 0.36
ALOX5 P09917 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Lithium SCHEMBL7177470 0.98 ITGB1 (0.48) ITGB1ITGA4THRATHRB
SCHEMBL7181077 0.98 ITGB1 (0.45) ITGB1ITGA4THRATHRBKDM4E
SCHEMBL28012984 0.96 ITGB1 (0.49) ITGB1ITGA4THRATHRB
SCHEMBL7177461 0.95 ITGB1 (0.48) ITGB1ITGA4THRATHRB
Lithium SCHEMBL7182492 0.95 ITGB1 (0.40) ITGB1ITGA4THRBKDM4ESMN1; SMN2
SCHEMBL7180599 0.94 ITGB1 (0.47) ITGB1ITGA4THRATHRB
SCHEMBL7182484 0.93 ITGB1 (0.40) ITGB1ITGA4THRBKDM4ESMN1; SMN2
Lithium SCHEMBL7188712 0.90 PPARG (0.43) THRBPPARGPPARAPTGESALOX5
Lithium SCHEMBL7183689 0.90 PPARG (0.37) ITGB1ITGA4THRATHRBHDAC6
Lithium SCHEMBL7177184 0.88 PPARG (0.37) ITGB1ITGA4THRATHRBKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6579663-B2 Chemical intermediates such as lithium 2,6-dimethylbenzoyl phenylphosphine for preparation of acylphosphines, acylphosphine oxides or acylphosphine sulfides CIBA SPECIALTY CHEMICALS CORPORATION 2003-06-17 US disclosed
US-20020107413-A1 Organometallic monoacylarylphosphines WOLF JEAN-PIERRE (CH) 2002-08-08 US disclosed
US-6399805-B2 SUCH AS LITHIUM 2,6-DIMETHYLBENZOYLPHENYLPHOSPHINE, USE AS PHOTOINITIATORS IN PHOTOCURABLE COMPOSITIONS SUCH AS FOR PHOTOGRAPHIC PRODUCTION OF RELIEF IMAGES CIBA SPECIALTY CHEMICALS CORPORATION 2002-06-04 US disclosed
US-20010031898-A1 Organometallic monoacylarylphosphines CIBA SPECIALTY CHEMICALS CORP. 2001-10-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020107413-A1 Organometallic monoacylarylphosphines CBR1, NAF1, DHCR24 ITGB1 2786/4885ITGA4 3521/4885THRA 1901/4885
US-20010031898-A1 Organometallic monoacylarylphosphines NAF1, DHCR24, CBR1 ITGB1 3321/4885ITGA4 3643/4885THRA 2159/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.